Edition:
India

Morphosys Says Its Licensee Janssen Has Expanded Clinical Development Of Guselkumab Into Ulcerative Colitis


Friday, 18 Jan 2019 

Jan 17 (Reuters) - MorphoSys AG ::MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB (TREMFYA(R)) INTO ULCERATIVE COLITIS.MORPHOSYS AG- JANSSEN HAS INITIATED A PROOF-OF-CONCEPT PHASE 2A CLINICAL TRIAL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS .MORPHOSYS IS ELIGIBLE TO CERTAIN MILESTONE PAYMENTS AND RECEIVES ROYALTIES ON NET SALES OF TREMFYA (R). 

Company Quote

105.8
-0.1 -0.09%
20 Sep 2019